Comparison of discovery rates and prognostic utility of 68GaGa-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study

Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.BACKGROU...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2024-07, Vol.51 (9), p.2833
Main Authors: Kluge, Kilian, Einspieler, Holger, Haberl, David, Spielvogel, Clemens, Amereller, Dominik, Egger, Gerda, Kramer, Gero, Grubmüller, Bernhard, Shariat, Shahrokh, Hacker, Marcus, Kenner, Lukas, Haug, Alexander
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.BACKGROUNDCirculating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.One hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [68Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall survival (OS) was evaluated.METHODSOne hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [68Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall survival (OS) was evaluated.PSMA PET discovery rates according to castration status and PSA ranges did differ significantly (P = 0.013, P 
ISSN:1619-7089
1619-7089
DOI:10.1007/s00259-024-06698-7